Opthea Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPT research report →
Range $2 – $2
Price Chart
About the company
Opthea Limited is an Australian biopharmaceutical company operating at the clinical development stage, focused on discovering and commercializing treatments primarily for ophthalmic conditions. Its research and development efforts are underpinned by an intellectual property portfolio that covers Vascular Endothelial Growth Factors (VEGF) C and D, along with VEGF Receptor-3. This proprietary foundation targets diseases stemming from abnormal blood and lymphatic vessel growth or vascular leakage.
- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- IPO
- 2020
- Employees
- 33
- HQ
- South Yarra, VIC, AU
Get TickerSpark's AI analysis on OPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $25.00K-79.9%
- Gross Profit
- $25.00K+15.1%
- Op Income
- $-156,588,020
- Net Income
- $-163,795,000+25.6%
- EPS
- $-1.04+62.9%
- OCF Growth
- +1.1%
- FCF Growth
- +1.1%
- 52W High
- $6.30
- 52W Low
- $1.79
- 50D MA
- $4.37
- 200D MA
- $3.53
- Beta
- 1.67
- RSI (14)
- 39
- Avg Volume
- 32.32K
No earnings-call transcripts are available for OPT yet.
- Free Float
- 63.1%
- Shares Outstanding
- 155.27M
- Float Shares
- 98.01M
of shares held by institutions
11 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Old Mission Capital, LLC | 11.48K | ▲ 11.48K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 6, 06 | HARROLD JASON M | sell | 784 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 15,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 7,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 11,250 |
| Mar 6, 06 | HARROLD JASON M | sell | 22,500 |
| Mar 6, 06 | HARROLD JASON M | sell | 125,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 25,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 45,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OPT coverage
Recent articles, reports, and earnings notes.
No research on OPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPT report →Cavendish lifts Optima Health target as annual profit beats forecasts
proactiveinvestors.co.uk · Aug 17
Optima Health targets further growth after transformational year
proactiveinvestors.co.uk · Aug 17
Optima Health trading 'in line' as it continues to grow UK and Ireland platform
proactiveinvestors.co.uk · Jun 16
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
feeds.benzinga.com · Jan 2
Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis
defenseworld.net · Dec 23
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Here’s What Happened
defenseworld.net · Nov 18
Opthea Provides Corporate Update
globenewswire.com · Aug 18
Opthea Announces Decision to Discontinue Wet AMD Trials
globenewswire.com · Mar 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.